Segment Reporting

6 Months Ended

Jun. 30, 2011

Segment Reporting

Segment Reporting

12. Segment Reporting

Prior to the sale of its interest in Microbia in September 2010, the Company had two reportable business segments: human therapeutics and biomanufacturing. The Company has no inter-segment revenues.

The following table reports revenue and loss from operations for the Company’s reportable segments for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Revenue:
Human therapeutics	$	11,262		$	9,188		$	21,499		$	18,026
Biomanufacturing (included in discontinued operations)	—			1,771			—			1,985
Total	$	11,262		$	10,959		$	21,499		$	20,011
Loss from operations:
Human therapeutics	$	(18,952	)	$	(17,310	)	$	(37,494	)	$	(31,806	)
Biomanufacturing (included in discontinued operations)	—			(9		)	—			(1,741		)
Total	$	(18,952	)	$	(17,319	)	$	(37,494	)	$	(33,547	)

	June 30,2011		December 31, 2010
Total assets:
Human therapeutics	$	249,727	$	301,365
Biomanufacturing (included in discontinued operations)	—		—
Total	$	249,727	$	301,365

At June 30, 2011 and December 31, 2010, all of the Company’s accounts receivable related to the human therapeutics segment.